MEDBOT-B (02252) saw its shares rise more than 3% ahead of its financial results announcement. By the time of writing, the stock had increased by 3.64% to HK$25.06, with a trading turnover of HK$206 million. The company is scheduled to hold a board meeting on March 26 to review and approve the full-year results for the period ending December 31, 2025, and release the corresponding announcement. MEDBOT-B previously disclosed that it expects revenue for the fiscal year ending December 31, 2025, to increase by approximately 110% to 120% year-over-year. Additionally, its adjusted net loss is projected to be no more than RMB 240 million, narrowing by over 50% compared to the previous year. The significant revenue surge is primarily attributed to breakthrough progress in the commercialization of its core product, the Toumai® laparoscopic surgical robot, which has experienced rapid sales growth. Notably, the expansion into overseas markets has yielded remarkable results, with over 100 new orders secured abroad during the year. Overseas market sales revenue for the full year was more than five times that of the previous year.